{"id":391199,"date":"2015-12-18T00:00:00","date_gmt":"2015-12-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus0715-biopharma-novel-classes-of-biologics-vs-tnf-alpha-inhibitors-for-crohns-disease-and-ulcerative-colitis\/"},"modified":"2026-04-22T17:29:23","modified_gmt":"2026-04-22T17:29:23","slug":"pforus0715-biopharma-novel-classes-of-biologics-vs-tnf-alpha-inhibitors-for-crohns-disease-and-ulcerative-colitis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforus0715-biopharma-novel-classes-of-biologics-vs-tnf-alpha-inhibitors-for-crohns-disease-and-ulcerative-colitis\/","title":{"rendered":"Novel Classes of Biologics vs. TNF-Alpha Inhibitors for Crohn&#8217;s Disease and Ulcerative Colitis | Physician &#038; Payer Forum | US | 2015"},"content":{"rendered":"<p>Crohn\u2019s disease (CD) and ulcerative colitis (UC) are the two gastrointestinal inflammatory disorders that constitute inflammatory bowel disease (IBD), affecting approximately 1.25 million people in the United States. Use of biologics is becoming more commonplace in these disorders, with five approved in the CD market and four in the UC market. Janssen\u2019s Remicade (infliximab) and AbbVie\u2019s Humira (adalimumab) are the contenders to beat for emerging agents vying for share in patients who are refractory to less expensive, conventional agents. U.S. gastroenterologists indicate a strong preference for novel agents with alternative mechanisms of action that can offer improvements on the key goals of CD\/UC pharmacotherapy: induction and maintenance of remission. In this report, we present key insights from physicians\u2019 and payers\u2019 opinions on current biologics and emerging therapies in order to address the potential actions necessary to keep pace with the evolving prescribing and reimbursement landscape for CD and UC. We focus on the available TNF-? inhibitors Remicade, Humira, Janssen\u2019s Simponi (golimumab), and UCB\u2019s Cimzia (certolizumab pegol); the cell adhesion molecule inhibitors Biogen\u2019s Tysabri (natalizumab) and Takeda\u2019s Entyvio (vedolizumab); and the emerging therapies Janssen\u2019s Stelara (ustekinumab) and Pfizer\u2019s Xeljanz (tofacitinib), as well as biosimilars infliximab and adalimumab.<\/p>\n","protected":false},"template":"","class_list":["post-391199","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-therapy-areas-ulcerative-colitis","biopharma-geography-us","biopharma-date-717"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391199","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391199\/revisions"}],"predecessor-version":[{"id":576905,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391199\/revisions\/576905"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391199"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}